close 73% inwestorów detalicznych traci pieniądze podczas handlu CFD z tym dostawcą. Inwestowanie wiąże się z ryzykiem i nie jest odpowiednie dla wszystkich inwestorów. Kontrakty CFD są złożonymi instrumentami i wiążą się z dużym ryzykiem szybkiej utraty środków pieniężnych z powodu dźwigni finansowej. 73% rachunków inwestorów detalicznych notuje stratę pieniędzy podczas handlu kontraktami CFD z tym dostawcą. Upewnij się, czy rozumiesz, jak działają kontrakty CFD, i czy możesz pozwolić sobie na wysokie ryzyko utraty pieniędzy.
Change languagePolski
Pulpit

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Strona główna・Stock List・Nektar Therapeutics
Search

Nektar Therapeutics

Open

71.3 0.31

Strong Buy

Price update 13 lut 2026, 20:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

70.56

Max

72.84

Key metrics

By Trading Economics

Income

6.1M

-36M

Sales

615K

12M

EPS

-1.87

Profit margin

-301.289

Employees

61

EBITDA

6.9M

-29M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+73.04% upside

Dividends

By Dow Jones

Next Earnings

11 mar 2026

Market Stats

By TradingEconomics

Market Cap

-386M

754M

Previous open

70.99

Previous close

71.3

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

0.5949 / 0.7406 Support & Resistance

Nektar Therapeutics Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 lut 2026, 23:21 UTC

Acquisitions, Mergers, Takeovers

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

DJ

Read

15 lut 2026, 23:45 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

DJ

Read

15 lut 2026, 23:40 UTC

Market Talk

Gold Falls on Possible Position Adjustments -- Market Talk

DJ

Read

15 lut 2026, 23:06 UTC

Earnings

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

DJ

Read

15 lut 2026, 23:04 UTC

Earnings

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

DJ

Read

15 lut 2026, 23:04 UTC

Earnings

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

DJ

Read

15 lut 2026, 23:01 UTC

Earnings

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

DJ

Read

15 lut 2026, 23:01 UTC

Earnings

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

DJ

Read

15 lut 2026, 22:53 UTC

Acquisitions, Mergers, Takeovers

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

DJ

Read

15 lut 2026, 22:53 UTC

Acquisitions, Mergers, Takeovers

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

DJ

Read

15 lut 2026, 22:52 UTC

Acquisitions, Mergers, Takeovers

Qube Shareholders to Receive A$5.20/Share in Cash

DJ

Read

15 lut 2026, 22:52 UTC

Acquisitions, Mergers, Takeovers

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

DJ

Read

15 lut 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

BlueScope CEO Tania Archibald Speaking on a Call With Media

DJ

Read

15 lut 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

DJ

Read

15 lut 2026, 22:16 UTC

Acquisitions, Mergers, Takeovers

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

DJ

Read

15 lut 2026, 22:14 UTC

Acquisitions, Mergers, Takeovers

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

DJ

Read

15 lut 2026, 22:14 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

DJ

Read

15 lut 2026, 20:48 UTC

Earnings

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

DJ

Read

15 lut 2026, 20:47 UTC

Earnings

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

DJ

Read

15 lut 2026, 20:46 UTC

Earnings

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

DJ

Read

15 lut 2026, 20:45 UTC

Earnings

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

DJ

Read

15 lut 2026, 20:44 UTC

Earnings

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

DJ

Read

15 lut 2026, 20:44 UTC

Earnings

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

DJ

Read

15 lut 2026, 20:43 UTC

Earnings

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

DJ

Read

15 lut 2026, 20:42 UTC

Earnings

BlueScope Net Debt A$2.2 Million at Dec. 31

DJ

Read

15 lut 2026, 20:42 UTC

Earnings

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

DJ

Read

15 lut 2026, 20:41 UTC

Earnings

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

DJ

Read

15 lut 2026, 20:40 UTC

Earnings

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

DJ

Read

15 lut 2026, 20:40 UTC

Earnings

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

DJ

Read

15 lut 2026, 20:39 UTC

Earnings

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

DJ

Read

Peer Comparison

Price change

Nektar Therapeutics Forecast

Price Target

By TipRanks

73.04% upside

12 Months Forecast

Average 123.43 USD  73.04%

High 165 USD

Low 102 USD

Based on 8 Wall Street analysts offering 12 month price targets forNektar Therapeutics - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

8

Buy

0

Hold

0

Sell

Based on 8 analysts giving stock ratings to Nektar Therapeutics - Dist in the past 3 months.

Technical Score

By Trading Central

0.5949 / 0.7406Support & Resistance

Short Term

Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Intermediate Term

Strong Bearish Evidence

All events are bearish.

Long Term

Bearish Evidence

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

Other stocks from the sector

LLY

Eli Lilly and Co.

1,040.03

↑ +0.29%

JNJ

Johnson and Johnson

243.3

↓-0.53%

ABBV

AbbVie Inc

231.41

↑ +1.75%

NVS

Novartis AG

162.81

↑ +1.21%

MRK

Merck & Co Inc.

121.33

↑ +1.83%
help-icon Live chat